2025
Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments
Pouyan N, Aday J, Harte S, Kaplan C, Williams D, Glynos N, Herberholz M, Kruger D, Barron J, Mashour G, Clauw D, Preller K, Schrepf A, Boehnke K. Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments. Journal Of Psychopharmacology 2025, 39: 489-498. PMID: 40323119, DOI: 10.1177/02698811251330763.Peer-Reviewed Original ResearchConceptsNaturalistic psychedelic usePsychedelic useSymptom changeSymptom improvementAssociated with symptom improvementEffects of psychedelicsPosttraumatic stress disorderIndividual perceptions of selfPerceptions of selfPRISM scoreRepresentations of illnessPsychedelic treatmentStress disorderGlobal ImpressionPsychedelic experiencePictorial representationPictorial Representation of IllnessRetrospective reportsSelf-PerceptionReduced identificationChange scoresRetrospectively assessed changesPGIC scoresPatient Global ImpressionConvenience sampleThe therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies
Weleff J, Pulido-Saavedra A, Aghaei A, Ing K, Arakelian M, Fontenele R, Nero N, Barnett B, Anand A, Bassir Nia A, Angarita G. The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies. Psychiatry Research 2025, 348: 116446. PMID: 40147088, DOI: 10.1016/j.psychres.2025.116446.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsOpioid use disorderStudies of psychedelicsSystematic review of clinical studiesUse disorderReview of clinical studiesTherapeutic effects of psychedelicsEffects of psychedelicsOpioid receptor systemApplications of psychedelicsClinical studiesMu-opioid receptorsNaturalistic studySerotonergic psychedelicsOpioid withdrawalPlacebo-controlled trialPsychedelicsSubstance useUnited States Food and Drug AdministrationStates Food and Drug AdministrationMu-opioidFood and Drug AdministrationSystematic reviewReceptor systemClinical study designDouble-blindThe Contribution of Psychotherapy in Potential Therapeutic Effects of Psychedelics for Treatment of Opioid Use Disorder
Bassir Nia A, Farahmand Y, Griffith G, Ardavan M, Angarita G, Anand A, Pittenger C. The Contribution of Psychotherapy in Potential Therapeutic Effects of Psychedelics for Treatment of Opioid Use Disorder. Current Addiction Reports 2025, 12: 20. DOI: 10.1007/s40429-025-00638-7.Peer-Reviewed Original ResearchEffects of psychedelicsOpioid use disorderConcurrent psychotherapyUse disorderTherapeutic effects of psychedelicsContribution of psychotherapyImpact of psychedelicsSubstance use disordersOpioid withdrawal symptomsTreatment of opioid use disorderFDA-approved medicationsOpioid use disorder treatmentPsychotherapy modalitiesPsychedelic treatmentPsychotherapy componentWithdrawal symptomsPsychotherapyPsychedelic trialsTherapy modelPsychedelicsAcute effectsDisordersAssociated with higher ratesTreatment discontinuationPotential therapeutic effectsEffects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Pulido-Saavedra A, Oliva H, Prudente T, Kitaneh R, Nunes E, Fogg C, Funaro M, Weleff J, Nia A, Angarita G. Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies. Cellular And Molecular Life Sciences 2025, 82: 49. PMID: 39833376, PMCID: PMC11747050, DOI: 10.1007/s00018-024-05519-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOpioid use disorderUse disorderPreclinical studiesClinical studiesReview of preclinical studiesConditioned place preferenceOpioid Self-AdministrationEffects of psychedelicsPreclinical in vivo studiesOpioid use disorder treatmentFrequency of administrationPlace preferencePotential therapeutic effectsSelf-AdministrationWithdrawal symptomsPreclinical findingsMechanism of actionSafety profilePain studiesPsychedelicsMethodological quality assessmentClinical evidenceCardiovascular riskOpioidWeb of Science
2024
Neurobiological Correlates of Psychedelic Experiences and Psychedelic-Associated Adverse Effects
Rieser N, Schmidt T, Preller K. Neurobiological Correlates of Psychedelic Experiences and Psychedelic-Associated Adverse Effects. Current Topics In Behavioral Neurosciences 2024, 1-20. PMID: 39080245, DOI: 10.1007/7854_2024_507.Peer-Reviewed Original ResearchCortico-striato-thalamo-corticalPsychedelic experiencePathophysiology of psychiatric illnessPsychedelic drug actionEffects of psychedelicsHuman neuroimaging studiesAcute drug effectsEffects of psychedelic drugsEntropic brain hypothesisNeurobiological correlatesEgo dissolutionNeural correlatesNeurobiological mechanismsNeuroimaging studiesNeural mechanismsPsychiatric illnessPsychedelic drugsBrain hypothesisDrug effectsPET measurementsSubacute adverse effectsDrug actionGeneral effectEmotional impactLong-term adverse effectsKnowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms
McCulloch D, Lopez J, Dalla C, Castrén E, Erritzoe D, Frokjaer V, Lundberg J, Preller K, Fisher P, Knudsen G. Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms. Neuroscience Applied 2024, 3: 103929. DOI: 10.1016/j.nsa.2023.103929.Peer-Reviewed Original ResearchSerotonin 2A receptorFunctional brain activityMechanism of actionClinical effectsPreclinical modelsBrain disordersClinical neuroimagingDose optimizationNeurotransmitter releaseEffects of psychedelicsBrain activitySex differencesPsychedelic drugsMolecular mechanismsKnowledge gapsPsychedelicsAppropriate behavioral modelsPreclinicalNeuroimagingReceptors
2023
Visualizing drug actions on dendrites: psilocybin and other classic psychedelics
Shao L, Liao C, Gregg I, Davoudian P, Savalia N, Delagarza K, Kwan A. Visualizing drug actions on dendrites: psilocybin and other classic psychedelics. 2023, btu2b.2. DOI: 10.1364/brain.2023.btu2b.2.Peer-Reviewed Original Research
2022
Psychedelics and Neural Plasticity: Therapeutic Implications
Grieco S, Castrén E, Knudsen G, Kwan A, Olson D, Zuo Y, Holmes T, Xu X. Psychedelics and Neural Plasticity: Therapeutic Implications. Journal Of Neuroscience 2022, 42: 8439-8449. PMID: 36351821, PMCID: PMC9665925, DOI: 10.1523/jneurosci.1121-22.2022.Peer-Reviewed Original ResearchConceptsTherapeutic effectNeural plasticityUnmet clinical needFunctional neural plasticityBrain-wide circuitsPsychedelic drugsClinical trialsBasic neuroscience questionsReceptor binding sitesTherapeutic implicationsBrain disordersClinical researchPsychedelic effectsBrain functionClinical needEffects of psychedelicsDrugsNeural mechanismsFuture studiesPsychedelicsGene expressionNeuroscience questionsClinicTrialsBibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies
Weleff J, Akiki T, Barnett B. Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies. Journal Of Psychoactive Drugs 2022, 55: 434-444. PMID: 36218281, DOI: 10.1080/02791072.2022.2133757.Peer-Reviewed Original ResearchLysergic acid diethylamidePsychedelic researchBibliometric analysisEffects of psychedelicsStudies of psychedelicsClinical psychedelic researchNon-research settingsPsychiatric treatmentN-dimethyltryptamineProportion of studiesAcid diethylamidePsilocybinPsychedelicsSubanalysis of studiesPsilocybin studiesDimethyltryptamineMDMARelevant articlesMescaline
2021
Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States
Davis A, Agin-Liebes G, España M, Pilecki B, Luoma J. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. Journal Of Psychoactive Drugs 2021, 54: 309-318. PMID: 34468293, DOI: 10.1080/02791072.2021.1971343.Peer-Reviewed Original ResearchConceptsEffects of psychedelicsPsychedelic-assisted therapyMental health treatmentPsychedelic treatmentClinical psychologistsPsychedelic therapyPsychedelic drugsPsychedelic experienceHealth treatmentNeurocognitive riskPsychologistsPsychedelicsPositive beliefsElectronic survey studyFavorable attitudesReduce stigmaParticipantsBeliefsIncreased educationSurvey studyUnited StatesAttitudesIncreased knowledgeTherapeutic useTreatment
2018
Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
Schindler EAD, Wallace RM, Sloshower JA, D’Souza D. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Frontiers In Pharmacology 2018, 9: 177. PMID: 29545753, PMCID: PMC5838010, DOI: 10.3389/fphar.2018.00177.Peer-Reviewed Original ResearchCluster headacheClassic serotonergic psychedelicsPersistent therapeutic effectEffects of psychedelicsPotential long-term effectsPsychedelic drugsSystem involvementHeadache disordersTherapeutic resultsPsychedelic-assisted therapyDrug classesTherapeutic effectLong-term effectsMood disordersTherapeutic benefitMethodologic considerationsNeuropsychiatric disordersNeuroendocrine systemPsychedelic effectsHeadacheBeneficial effectsSerotonergic psychedelicsDisordersDrugsRecent reports
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply